

Curriculum Vitae

Personal information **Liana Martirosyan**

Work experience

1. Employer: Medicines Evaluation Board
 - Start date: 11/2023
 - Position: Dutch PRAC member, PRAC vice-chair
 - Country: Netherlands
2. Employer: Medicines Evaluation Board
 - Start date: 09/2018
 - End date: 10/ 2023
 - Position: Alternate PRAC member
 - Country: Netherlands
3. Employer: Medicines Evaluation Board
 - Start date: 01/2012
 - End date: 08/2018
 - Position: (Senior) pharmacovigilance assessor
 - Country: Netherlands
4. Employer: Netherlands health Services Research Institute (Nivel)
 - Start date: 01/2010
 - End date: 01/2012
 - Position: Epidemiologist, advisor to WHO/Europe
 - Activities: Coordination of Influenza surveillance programm in 53 countries of WHO/European region
 - Country: Netherlands

Education and training

1. Subject:
 - Qualification: PhD in Medical Science/pharmacoepidemiology
 - Country: Netherlands
2. Subject:
 - Qualification: Master in Public Health
 - Country: United States
3. Subject:
 - Qualification: Medical Doctor
 - Country: Netherlands

Additional information

Publications

T Goedecke , L Martirosyan , N. Gault, K. Seifert, DR Morales, P. Bahri, V. Strassmann, M. Huber, S. Straus. Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations. *Pharmacoepidemiol Drug Saf.* 2024 Aug;33(8):e5874 doi: 10.1002/pds.5874.

R Munoz, S., Postmus, D., de Vries, S.T. et al, L Martirosyan et al. What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. *Drug Saf* 46, 243–255 (2023). <https://doi.org/10.1007/s40264-022-01270-4> F.

van Hunsel, E de Jong, L Martirosyan, J. Hoekman. Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions. *Pharmacoepidemiol Drug Saf.* 2021 Aug;30(8):1115_1122. doi: 10.1002/pds.5246. Epub 2021 Apr 21. PMID: 33840136.

W. N. Insani, A. C. Pacurariu, a. K. Mantel_Teeuwisse, L. Martirosyan. Characteristics of drugs safety signals that predict safety related product information update in the EU. *Pharmacoepidemiol Drug Safety*, 2018 Jul;27(7):789_796

A. C. Pacurariu , P.M. Coloma, L. Martirosyan , M. C. Sturkenboom , S. M. Straus. Decision making in drug safety _ A literature review of criteria used to prioritize newly detected safety issues. *Pharmacoepidemiology and Drug Safety*, Oct 2016; DOI: 10.1002/pds.4128

Ekhart C, de Jong L, Martirosyan L, van Hunsel F. Muscle rupture associated with statin use. *Br J Clin Pharmacol.* 2016 Aug;82(2):473_7. doi: 10.1111/bcp.12973

L. Martirosyan, C. Geluk, S. Straus, B. Voordouw. New pharmacovigilance regulation and anti_infective medicinal products (Farmacovigilantie wetgeving en anti_infectieuze middelen). *Ned Tijdschr Med Microbiol* 2012;20:nr4

L. Martirosyan, J. W. Paget, P. Jorgensen, C. S. Brown, T. J. Meerhoff, D. Pereyaslov, and J. A. Mott on behalf of the EuroFlu group. The Signature Features of the 2009 Influenza Pandemic in the WHO European Region: a Comparison with Historical Seasonal Data from 28 Countries. *BMC Infectious Diseases* 2012, 12:36

L. Martirosyan, J Braspenning, P Denig, W J C de Grauw, M Bouma, F Storms, F M Haaijer_Ruskamp. Prescribing quality indicators for diabetes ambulatory care, Quality and Safety in Health Care 2008;17:318_323

L.Martirosyan, F.M. Haaijer_Ruskamp, J. Braspenning, P. Denig. Development of a Minimal Set of Prescribing Quality Indicators for Diabetes Management. *Pharmacoepidemiology and drug safety* 2012;21(10):1053_9

L. Martirosyan, O. Arah, F. M. Haaijer_Ruskamp, J. Braspenning, P. Denig, Methods to Identify the Target Population: Implications for Prescribing Indicators. BMC Health Services Research 2010, 10:137

J. Markhorst, L. Martirosyan, H. Calsbeek, J. Braspenning. Stakeholders' perspectives on quality indicators for diabetes care: a qualitative study. Quality in Primary Care 2012;20:253_61

L. Martirosyan, J. Markhorst, P. Denig, F.M. Haaijer_Ruskamp, J. Braspenning. Stakeholders' preferences in the Netherlands regarding prescribing quality information for diabetes management. BMC Health Services Research 2012, 12:191

L. Martirosyan, J. Voorham, F.M. Haaijer_Ruskamp, J. Braspenning, B.H.R. Wolffenbuttel, P. Denig. A Systematic Literature Review: Prescribing Quality Indicators for Type 2 Diabetes Mellitus and Cardiovascular Risk Management. Pharmacoepidemiology and Drug Safety 2010;19(4):319_334

Projects

Memberships

Other Relevant Information